Document Type

Article

Publication Date

5-27-2022

Identifier

DOI: 10.1038/s41467-022-30649-1; PMCID: PMC9142524

Abstract

Neutralization capacity of antibodies against Omicron after a prior SARS-CoV-2 infection in children and adolescents is not well studied. Therefore, we evaluated virus-neutralizing capacity against SARS-CoV-2 Alpha, Beta, Gamma, Delta and Omicron variants by age-stratified analyses (5 years of age. As expected, convalescent pediatric COVID-19 and MIS-C cohorts demonstrate higher neutralization titers than hospitalized acute COVID-19 patients. Overall, children and adolescents show some loss of cross-neutralization against all variants, with the most pronounced loss against Omicron. In contrast to SARS-CoV-2 infection, children vaccinated twice demonstrated higher titers against Alpha, Beta, Gamma, Delta and Omicron. These findings can influence transmission, re-infection and the clinical disease outcome from emerging SARS-CoV-2 variants and supports the need for vaccination in children.

Journal Title

Nat Commun

Volume

13

Issue

1

First Page

2979

Last Page

2979

MeSH Keywords

Adolescent; Antibodies, Viral; COVID-19; Child; Child, Preschool; Humans; Membrane Glycoproteins; Neutralization Tests; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Systemic Inflammatory Response Syndrome; Viral Envelope Proteins

Keywords

Viral Antibodies; COVID-19; Membrane Glycoproteins; Neutralization Tests; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Systemic Inflammatory Response Syndrome; Viral Envelope Proteins

Comments

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Publisher's Link: https://www.nature.com/articles/s41467-022-30649-1

Share

COinS